Evolution of Mesenchymal Stem Cell Therapy As an Advanced Therapeutic Medicinal Product (ATMP)-An Indian Perspective

Overview

Journal Bioengineering (Basel)

Date 2022 Mar 24

PMID 35324800

Authors

Sathish Muthu

Madhan Jeyaraman

Moinuddin Basha Kotner

Naveen Jeyaraman

Ramya Lakshmi Rajendran

Shilpa Sharma

Manish Khanna

Sree Naga Sowndary Rajendran

Ji Min Oh

Prakash Gangadaran

Byeong-Cheol Ahn

Affiliations

Soon will be listed here.

Abstract

Stem cells can be defined as the cells that have the capacity to both self-renew and give rise to differentiated cells. Under the right conditions and signals, depending on their origin and bio-plasticity, stem cells can differentiate into multiple cell lineages and develop into various mature cells. Stem cell therapy is a fast-developing branch of medicine that includes the most innovative regenerative therapies for the restoration of cell and tissue function in individuals with severe diseases. Stem cell research has resulted in the emergence of cell-based therapies for disorders that are resistant to conventional drugs and therapies, and they are considered under the category of an Advanced Therapeutic Medicinal Product (ATMP). The FDA and the European Medicines Agency (EMA) devised a new strategy in 2017 with the aim of unifying the standards for development of ATMPs such that it is easy to exchange information at the international level. In this review, we discuss the evolution of mesenchymal stem cell-based therapy as an ATMP in the global and Indian scenarios, along with the guidelines governing their usage and clinical application of these therapeutics.

Citing Articles

Bioengineering breakthroughs: The impact of stem cell models on advanced therapy medicinal product development.

Granjeiro J, Borchio P, Ribeiro I, Paiva K World J Stem Cells. 2024; 16(10):860-872.

PMID: 39493828 PMC: 11525646. DOI: 10.4252/wjsc.v16.i10.860.

Barriers and Solutions Towards Integrating Orthobiologics into Clinical Orthopaedic Practice.

Jeyaraman M, Muthu S, Amarnath S Indian J Orthop. 2024; 58(8):987-990.

PMID: 39087048 PMC: 11286904. DOI: 10.1007/s43465-024-01221-4.

Effect of Cellular Dosage of Bone Marrow Aspiration Concentrate on the Radiological Outcomes in Knee Osteoarthritis: A Phase I Dose-Escalation Study.

Muthu S, Ramanathan K, Yadav S, Jha S, Ranjan R Indian J Orthop. 2024; 58(8):1035-1042.

PMID: 39087044 PMC: 11286885. DOI: 10.1007/s43465-024-01201-8.

Increased Cellular Dosage of Bone Marrow Aspiration Concentrate Does Not Translate to Increased Clinical Effectiveness in Knee Osteoarthritis: A Phase I Dose Escalation Study.

Muthu S, Ramanathan K, Yadav S, Jha S, Ranjan R Indian J Orthop. 2024; 58(8):1001-1008.

PMID: 39087042 PMC: 11286881. DOI: 10.1007/s43465-024-01197-1.

Immune-Cell-Based Therapy for COVID-19: Current Status.

Wang Y, Liang Q, Chen F, Zheng J, Chen Y, Chen Z Viruses. 2023; 15(11).

PMID: 38005826 PMC: 10674523. DOI: 10.3390/v15112148.

References

Holbein M . Understanding FDA regulatory requirements for investigational new drug applications for sponsor-investigators. J Investig Med. 2009; 57(6):688-94. PMC: 4435682. DOI: 10.2310/JIM.0b013e3181afdb26. View

Iglesias-Lopez C, Agusti A, Obach M, Vallano A . Regulatory Framework for Advanced Therapy Medicinal Products in Europe and United States. Front Pharmacol. 2019; 10:921. PMC: 6728416. DOI: 10.3389/fphar.2019.00921. View

Heinonen M, Oila O, Nordstrom K . Current issues in the regulation of human tissue-engineering products in the European Union. Tissue Eng. 2006; 11(11-12):1905-11. DOI: 10.1089/ten.2005.11.1905. View

Pereira S, Veeraraghavan P, Ghosh S, Gandhi M . Animal experimentation and ethics in India: the CPCSEA makes a difference. Altern Lab Anim. 2013; 32 Suppl 1B:411-5. DOI: 10.1177/026119290403201s67. View

Hmadcha A, Martin-Montalvo A, Gauthier B, Soria B, Capilla-Gonzalez V . Therapeutic Potential of Mesenchymal Stem Cells for Cancer Therapy. Front Bioeng Biotechnol. 2020; 8:43. PMC: 7013101. DOI: 10.3389/fbioe.2020.00043. View

Henig I, Zuckerman T . Hematopoietic stem cell transplantation-50 years of evolution and future perspectives. Rambam Maimonides Med J. 2014; 5(4):e0028. PMC: 4222417. DOI: 10.5041/RMMJ.10162. View

Zhuang W, Lin Y, Su L, Wu M, Jeng H, Chang H . Mesenchymal stem/stromal cell-based therapy: mechanism, systemic safety and biodistribution for precision clinical applications. J Biomed Sci. 2021; 28(1):28. PMC: 8043779. DOI: 10.1186/s12929-021-00725-7. View

Viswanathan S, Rao M, Keating A, Srivastava A . Overcoming challenges to initiating cell therapy clinical trials in rapidly developing countries: India as a model. Stem Cells Transl Med. 2013; 2(8):607-13. PMC: 3726140. DOI: 10.5966/sctm.2013-0019. View

. Biological products regulated under Section 351 of the Public Health Service Act; implementation of biologics license; elimination of establishment license and product license; public workshop--FDA. Proposed rule; notice of workshop. Fed Regist. 1998; 63(154):42773-4. View

10.

Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D . Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006; 8(4):315-7. DOI: 10.1080/14653240600855905. View

11.

Chagastelles P, Nardi N . Biology of stem cells: an overview. Kidney Int Suppl (2011). 2014; 1(3):63-67. PMC: 4089750. DOI: 10.1038/kisup.2011.15. View

12.

Lahiry S, Choudhury S, Sinha R, Chatterjee S . The National Guidelines for Stem Cell Research (2017): What academicians need to know?. Perspect Clin Res. 2019; 10(4):148-154. PMC: 6801994. DOI: 10.4103/picr.PICR_23_18. View

13.

Levy O, Kuai R, Siren E, Bhere D, Milton Y, Nissar N . Shattering barriers toward clinically meaningful MSC therapies. Sci Adv. 2020; 6(30):eaba6884. PMC: 7439491. DOI: 10.1126/sciadv.aba6884. View

14.

Pittenger M, Discher D, Peault B, Phinney D, Hare J, Caplan A . Mesenchymal stem cell perspective: cell biology to clinical progress. NPJ Regen Med. 2019; 4:22. PMC: 6889290. DOI: 10.1038/s41536-019-0083-6. View

15.

Parekkadan B, Milwid J . Mesenchymal stem cells as therapeutics. Annu Rev Biomed Eng. 2010; 12:87-117. PMC: 3759519. DOI: 10.1146/annurev-bioeng-070909-105309. View

16.

Goula A, Gkioka V, Michalopoulos E, Katsimpoulas M, Noutsias M, Sarri E . Advanced Therapy Medicinal Products Challenges and Perspectives in Regenerative Medicine. J Clin Med Res. 2021; 12(12):780-786. PMC: 7781285. DOI: 10.14740/jocmr3964. View

17.

Horgan D, Metspalu A, Ouillade M, Athanasiou D, Pasi J, Adjali O . Propelling Healthcare with Advanced Therapy Medicinal Products: A Policy Discussion. Biomed Hub. 2021; 5(3):130-152. PMC: 8101061. DOI: 10.1159/000511678. View

18.

Mendicino M, Bailey A, Wonnacott K, Puri R, Bauer S . MSC-based product characterization for clinical trials: an FDA perspective. Cell Stem Cell. 2014; 14(2):141-5. DOI: 10.1016/j.stem.2014.01.013. View

19.

Ullah I, Subbarao R, Rho G . Human mesenchymal stem cells - current trends and future prospective. Biosci Rep. 2015; 35(2). PMC: 4413017. DOI: 10.1042/BSR20150025. View

20.

Schneider C, Salmikangas P, Jilma B, Flamion B, Todorova L, Paphitou A . Challenges with advanced therapy medicinal products and how to meet them. Nat Rev Drug Discov. 2010; 9(3):195-201. DOI: 10.1038/nrd3052. View